IceCure Medical (ICCM) expects product sales of $525K for the three months ended June 30. More than $200K of product sales for shipments that were scheduled for delivery during Q2 are expected to be delivered in July, and the associated product sales booked during Q3. Pproduct sales for the six months ended June 30 was approximately $1.25M vs. $1.65M during the six months ended June 30, 2024. Product sales for the six-month period ended June 30, 2024 excludes revenue of $100K received from the exclusive distribution agreement with Terumo and other services in Japan. The company expects sales to fluctuate quarter-over-quarter due to the timing of customer orders and shipments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical Launches $10 Million Rights Offering
- IceCure Medical announces rights offering for up to $10M
- IceCure Medical Secures U.S. Patent Allowance for Cryogen Flow Control
- IceCure receives Notice of Allowance from USPTO for ‘Cryogen Flow Control’
- Buy Rating for Icecure Medical: Anticipated FDA Approval and Strategic Partnerships Drive Positive Outlook